Home > Back to Publisher > Report Information

Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Renub Research
June 21, 2010
114 Pages - SKU: RNBR2707161

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

“Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:

Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
Region wise Diabetes Health Expenditure and Mortality
Top 10 Countries Diabetes Population and Future Forecast
Top 5 Countries Diabetes Drug Market and Future Forecast
Top 7 Countries Insulin Market and Future Forecast
Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

USA controls more than 50% of the total Diabetes Drug market share in 2009
Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
China will have the second highest Insulin market share by 2012 replacing Germany
DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
GLP-1 Agonists
Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
Januvia is proving a blockbuster of DPP - IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Key Drugs Analyzed

Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

1. Executive Summary
2. Global Diabetes Market: 2.1 Global - Diabetes Drug Market & Future Forecast; 2.2 Global - Insulin Market & Future Forecast; 2.3 Global - Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India); 2.4 Global - Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan, USA, India); 2.5 Global - Dipeptidyl Peptidase (DPP - IV) Inhibitors Market & Future Forecast; 2.6 Global - Glucagon-like Peptide-1(GLP-1) Market & Future Forecast
3. Global - Top 6 Diabetes Drug Brands Market Performance: 3.1 Avandia - Past & Present Market; 3.2 Actos - Past, Present & Future Forecast; 3.3 Amaryl - Past, Present & Future Forecast; 3.4 Avandamet - Past, Present & Future Forecast; 3.5 Prandin/Novonorm - Past & Present Market; 3.6 Starlix - Past, Present & Future Forecast
4. Global - Top 9 Insulin Brands Market Performance: 4.1 Novomix - Past, Present & Future Forecast; 4.2 Novorapid - Past, Present & Future Forecast; 4.3 Levemir - Past, Present & Future Forecast; 4.4 Degludec - Yet to be Launched - Future Forecast; 4.5 Degludecplus - Yet to be Launched - Future Forecast; 4.6 Humalog - Past & Present Market; 4.7 Humulin - Past & Present Market; 4.8 Apidra - Past, Present & Future Forecast; 4.9 Lantus - Past, Present & Future Forecast
5. Global - DPP-IV Inhibitors Brands Market Performance: 5.1 Januvia - Past, Present & Future Forecast; 5.2 Onglyza - Past, Present & Future Forecast; 5.3 Alogliptin - Yet to be Launched - Future Forecast; 5.4 Galvus - Past, Present & Future Forecast; 5.5 DPP-IV Inhibitors - In Trial Phases
6. Global - GLP-1 Agonists Brands Market Performance: 6.1 Byetta - Past, Present & Future Forecast; 6.2 Victoza - Past, Present & Future Forecast; 6.3 Exenatide LAR - Yet to be Launched - Future Forecast; 6.4 Syncria - Yet to be Launched - Future Forecast; 6.5 Taspoglutide - Yet to be Launched - Future Forecast
7. Regional Estimates for Diabetes: 7.1 Diabetes - Population & Prevalence; 7.2 Impaired Glucose Tolerance (IGT) - Population & Prevalence; 7.3 Mortality - Due to Diabetes; 7.4 North America & Caribbean Region; 7.5 Middle East and North African Region; 7.6 South-East Asian Region; 7.7 European Region; 7.8 South and Central American Region; 7.9 Western Pacific Region; 7.10 African Region
8. Global - Top 10 Diabetic Countries Performance: 8.1 Number of People in Top 10 Diabetic Place; 8.2 Prevalence of Diabetes in Top 10 Countries; 8.3 India; 8.4 China; 8.5 United States; 8.6 Brazil; 8.7 Russia; 8.8 Japan; 8.9 Germany; 8.10 Mexico; 8.11 Indonesia; 8.12 Pakistan
List of Figures:: Figure 2 1: Global - Diabetes Drug Market (Billion US$), 2005 - 2009; Figure 2 2: Global - Forecast of Diabetes Drug Market (Billion US$), 2010 - 2013; Figure 2 3: Global - Insulin Market (Billion US$), 2004 - 2009; Figure 2 4: Global - Forecast of Insulin Market (Billion US$), 2010 - 2013; Figure 2 5: Global - Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 - 2009; Figure 2 6: Global - Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2010 - 2013; Figure 2 7: Global - Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2007 - 2009; Figure 2 8: Global - Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2010 - 2013; Figure 2 9: Global - DPP - IV Inhibitors Market (Million US$), 2009 - 2015; Figure 2 10: Global - GLP-1 Market (Million US$), 2009 - 2015; Figure 3 1: Global - Avandia Diabetes Drug Brand Sales (Million US$), 2004 - 2009; Figure 3 2: Global - Actos Diabetes Drug Sales (Billion US$), 2005 - 2009; Figure 3 3: Global - Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013; Figure 3 4: Global - Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010; Figure 3 5: Global - Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 - 2012; Figure 3 6: Global - Avandamet Diabetes Drug Sales (Million US$), 2006 - 2009; Figure 3 7: Global - Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 - 2012; Figure 3 8: Global - Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 - 2009; Figure 3 9: Global - Starlix Diabetes Drug Sales (Million US$), 2007 - 2009E; Figure 3 10: Global - Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 - 2012; Figure 4 1: Global - NovoMix Insulin Sales (Million US$), 2005 - 2009; Figure 4 2: Global - NovoRapid Insulin Sales (Million US$), 2005 - 2009; Figure 4 3: Global - Levemir Insulin Sales (Million US$), 2005 - 2009; Figure 4 4: Global - Humalog Insulin Sales (Million US$), 2006 - 2009; Figure 4 5: Global - Humulin Insulin Brand Sales (Million US$), 2006 - 2009; Figure 4 6: Global - Apidra Insulin Sales (Million US$), 2005 - 2009, Q1 2010; Figure 4 7: Apidra - Forecast for Insulin Sales (Million US$), 2009 - 2013; Figure 4 8: Global - Lantus Insulin Sales (Million US$), 2006 - 2009, Q1 2010; Figure 4 9: Global - Forecast for Lantus Insulin Sales (Million US$), 2010 - 2015; Figure 5 1: Global - Januvia DPP-IV Inhibitors Sales (Million US$), 2007 - 2009; Figure 5 2: Global - Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 - 2017; Figure 5 3: Global - Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 - 2017; Figure 5 4: Global - Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 - 2017; Figure 5 5: Global - Galvus DPP-IV Inhibitors Sale (Million US$), 2007 - 2009; Figure 5 6: Global - Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 - 2012; Figure 6 1: Global - Byetta GLP-1 Sales (Million US$), 2006 - 2009; Figure 6 2: Global - Forecast for Byetta GLP-1 Sales (Million US$), 2010 - 2017; Figure 6 3: Global - Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 - 2017; Figure 6 4: Global - Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 - 2017; Figure 6 5: Global - Forecast for Syncria GLP-1 Sales (Million US$), 2013 - 2017; Figure 6 6: Global - Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 - 2017; Figure 8 1: India - Number of People with Diabetes (Million), 2003, 2007, 2010; Figure 8 2: India - Diabetes Drug Market (Billion INR), 2006 - 2009; Figure 8 3: India - Forecast for Diabetes Drug Market (Billion INR), 2010 - 2014; Figure 8 4: India - Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in Percent), 2003 & 2007; Figure 8 5: India - Insulin Market (Million INR), 2006 - 2009; Figure 8 6: India - Forecast for Insulin Market (Million INR), 2010 - 2014; Figure 8 7: China - Number of Diabetes Patients (Million), 2003, 2007 & 2010; Figure 8 8: China - Diabetes Drug Market (Billion Yuan), 2006 - 2009E; Figure 8 9: China - Forecast for Diabetes Drug Market (Billion Yuan) 2010 - 2014; Figure 8 10: China - Insulin Market (Million Yuan), 2007 - 2009; Figure 8 11: China - Forecast for Insulin Market (Million Yuan), 2010 - 2014; Figure 8 12: USA - Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010; Figure 8 13: USA - Diabetes Drug Market (Million US$), 2002 - 2009; Figure 8 14: USA - Forecast for Diabetes Drug Market (Million US$), 2010 - 2014; Figure 8 15: USA - Insulin Market (Billion US$), 2003 - 2009; Figure 8 16: USA - Forecast for Insulin Market (Billion US$), 2010 - 2014; Figure 8 17: Brazil - Diabetes Population (Million), 2003, 2007 & 2010; Figure 8 18: Brazil - Diabetes Drug Market (Million US$), 2008 - 2013; Figure 8 19: Russia - Number of Diabetes Population (Million), 2005 & 2010; Figure 8 20: Russia - Insulin Market (Million US$), 2002, 2005 - 2009; Figure 8 21: Russia - Forecast for Insulin Market (Million US$), 2010 - 2014; Figure 8 22: Japan - Number of Diabetes Population (Million), 2003 - 2010; Figure 8 23: Japan - Diabetes Drug Market (Million US$), 2002 - 2009; Figure 8 24: Japan - Forecast for Diabetes Market (Million US$), 2010 - 2014; Figure 8 25: Japan - Insulin Market (Million US$), 1998 - 2009; Figure 8 26: Japan - Forecast for Insulin Market (Million US$), 2010 - 2014; Figure 8 27: Germany - Number of Diabetes Patients (Million), 2003 - 2010; Figure 8 28: Germany - Insulin Market (Million US$), 2004 - 2009E; Figure 8 29: Germany - Forecast for Insulin Market (Billion US$), 2010 - 2014; Figure 8 30: Mexico - Number of People with Diabetes (Million), 2003 - 2005, 2007 & 2010; Figure 8 31: Mexico - Insulin Market (Million US$), 2004 - 2009E; Figure 8 32: Mexico - Forecast for Insulin Market (Million US$), 2010 - 2014; Figure 8 33: Pakistan - Number of Diabetes Patients (Million), 2003, 2007 & 2010
List of Tables:: Table 4 1: Novomix - Forecast for Insulin Sales (Million US$), 2010 - 2030; Table 4 2: Global - Forecast for NovoRapid Insulin Sales (Million US$), 2010 - 2030; Table 4 3: Global - Forecast for Levemir Insulin Sales (Million US$), 2010 - 2030; Table 4 4: Degludec - Forecast for Insulin Sales (Million US$), 2010 - 2030; Table 4 5: DegludecPlus - Forecast for Insulin Sales (Million US$), 2010 - 2030; Table 5 1: DPP-4 Inhibitors -In Trial Phase; Table 7 1: Regional - Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence %) (20-79 years), 2010 and 2030; Table 7 2: Regional - Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79 years), 2010 and 2030; Table 7 3: Regional - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 4: North America and Caribbean Region - Population & Adult Population (Million), 2010 & 2030; Table 7 5: North America and Caribbean Region - Number of People with Diabetes & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030; Table 7 6: North America and Caribbean Region - Number of People with IGT & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030; Table 7 7: North America and Caribbean Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 8: North America and Caribbean Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 9: Middle East and North African Region - Population & Adult Population (Million), 2010 & 2030; Table 7 10: Middle East and North African Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 11: Middle East and North African Region - Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 12: Middle East and North African Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 13: Middle East and North African Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 14: South-East Asian Region - Population & Adult Population (Million), 2010 & 2030; Table 7 15: South-East Asian Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 16: South-East Asian Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 17: South-East Asian Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 18: European Region - Population & Adult Population (Million), 2010 & 2030; Table 7 19: European Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million Percent), 2010 & 2030; Table 7 20: European Region - Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 21: European Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 22: European Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 23: South and Central American Region - Population & Adult Population (Million), 2010 & 2030; Table 7 24: South and Central American Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 25: South and Central American Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 26: South and Central American Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 27: Western Pacific Region - Population & Adult Population (Million), 2010 & 2030; Table 7 28: Western Pacific Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 29: Western Pacific Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 30: Western Pacific Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 7 31: African Region - Population & Adult Population (Million), 2010 & 2030; Table 7 32: African Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 33: African Region - Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030; Table 7 34: African Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030; Table 7 35: African Region - Diabetes Mortality (20-79 Years; Thousand), 2010; Table 8 1: Global - Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 & 2030; Table 8 2: Global - Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 & 2030; Table 8 3: India - Forecast for Number of People with Diabetes (Million), 2011 - 2030; Table 8 4: China - Forecast for Number of Diabetes Patients (Million), 2011 - 2030; Table 8 5: USA - Forecast for Number of Diabetes Patients (Million), 2011 - 2030; Table 8 6: Brazil - Forecast for Number of Diabetes Population (Million), 2011 - 2030; Table 8 7: Russia - Forecast for Number of Diabetes Population (Million), 2011 - 2030; Table 8 8: Mexico - Forecast for Number of Diabetes Patients (Million), 2011 - 2030; Table 8 9: Indonesia - Forecast for Number of Diabetes Patients (Million), 2010 - 2030; Table 8 10: Pakistan - Forecast for Number of Diabetes Patients (Million), 2011 - 2030

More Global Research & Development Reports

Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity by GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity Summary GBI Research, the leading ...

Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity by GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity Summary ...

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition by Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, ...

Top 700 Medical & Scientific Research (Global) by Plimsoll Publishing Ltd.
This report is an in-depth financial evaluation of the GlobalMedical & Scientific Research . Using the unique Plimsoll method of analysis, each of the top ...

Ophthalmic Drugs: World Market Prospects 2012-2022 by Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry What are the commercial prospects for treating eye disorders? Visiongain's report shows you ...

See all reports like this >>

Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service